Floatz Rating
B63/100
Confidence
Indicative
Sponsor
M.D. Anderson Cancer Center
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
52High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05703854CT.gov Study of CAR.70-engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Advanced Renal Cell Carcinoma, Mesothelioma and Osteosarcoma | — | Recruiting | — | — | — |
NCT05492682CT.gov START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer | — | Recruiting | — | — | — |
NCT04897321CT.gov B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR) | — | Recruiting | — | — | — |
NCT04282044CT.gov Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies | — | Recruiting | — | — | — |
NCT04483778CT.gov B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults | — | Active Not Recruiting | — | — | — |
NCT03721068CT.gov Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma or Relapsed/Refractory Osteosarcoma | — | Recruiting | — | — | — |
NCT03449108CT.gov LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas | — | Active Not Recruiting | — | — | — |
NCT02517918CT.gov Metronomic Chemotherapy in Patients With Advanced Solid Tumor With Bone Metastasis and Advanced Pretreated Osteosarcoma | — | Completed | — | — | — |
NCT02107963CT.gov A Phase I Trial of T Cells Expressing an Anti-GD2 Chimeric Antigen Receptor in Children and Young Adults With GD2+ Solid Tumors | — | Completed | — | — | — |
NCT02013336CT.gov Phase 1 Dose-escalating Study of MM-398 (Irinotecan Sucrosofate Liposome Injection) Plus Intravenous Cyclophosphamide in Recurrent or Refractory Pediatric Solid Tumors | — | Unknown | — | — | — |
Show 2 more trialsShow fewer
NCT01661400CT.gov Anti-Angiogenic Therapy Post Transplant (ASCR) for Pediatric Solid Tumors | — | Completed | — | — | — |
NCT01154816CT.gov Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Osteosarcoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Cyclophosphamide (this asset) | M.D. Anderson Cancer Center | P2 | B · 63 |
| (+)-Vincristine | Milton S. Hershey Medical Center | P2 | BB |
| Ipilimumab | Children's National Research Institute | P2 | BB |
| Olaparib | Fundación de investigación HM | P2 | BB |
| Irinotecan | Milton S. Hershey Medical Center | P2 | B |
| Oxaliplatin | National Cancer Institute (NCI) | P2 | B |
| Etoposide | Eisai Limited | P2 | B |
| Nivolumab | Instituto do Cancer do Estado de São Paulo | P2 | B |
| Cixutumumab | National Cancer Institute (NCI) | P2 | B |
+42 more in the Osteosarcoma cohort
Other indications for Cyclophosphamide
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Adult Acute Lymphoblastic Leukemia | — | P4 | BBB · 79 |
| Mycosis Fungoides | — | P4 | BBB · 78 |
| B-Cell Childhood Acute Lymphoblastic Leukemia | — | P3 | BBB · 78 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Cyclophosphamide in Osteosarcoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/cyclophosphamide-osteosarcoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →